This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • U.S. government commits to purchase approximately ...
News

U.S. government commits to purchase approximately 1.7 million courses of molnupiravir upon issuance of Emergency Use Authorization or approval by the FDA.- Merck Inc.

Read time: 1 mins
Published:11th Jun 2021
Merck Inc., announced it has entered into a procurement agreement with the United States government for molnupiravir (MK-4482). Molnupiravir is currently being evaluated in a Phase III clinical trial, the MOVe-OUT study, for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes.

Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. Through the agreement, if molnupiravir receives Emergency Use Authorization (EUA) or approval by the FDA, Merck will receive approximately $1.2 billion to supply approximately 1.7 million courses of molnupiravir to the United States government. Merck has been investing at risk to support development and scale-up production of molnupiravir and expects to have more than 10 million courses of therapy available by the end of 2021. Merck also plans to submit applications for emergency use or approval to regulatory bodies outside of the U.S. and is currently in discussions with other countries interested in advance purchase agreements for molnupiravir. Merck is committed to providing timely access to molnupiravir globally and intends to implement a tiered pricing approach based on World Bank data that recognizes countries’ relative ability to finance their public health response to the pandemic. If successful in clinical testing, molnupiravir has the chance to become the first oral COVID-19 treatment, an improvement over the injectable and infused medicines now available.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.